Urinary biomarkers of bladder cancer: an update and future perspectives

    Authors

    C. J. Rosser; V. Urquidi;S. Goodison

    Comments

    Authors: contact us about adding a copy of your work at STARS@ucf.edu

    Abbreviated Journal Title

    Biomark. Med.

    Keywords

    biomarker; bladder cancer; genomics; metabolomics; proteomics; urinary; cytology; urine; TRANSITIONAL-CELL CARCINOMA; IN-SITU HYBRIDIZATION; NUCLEAR-MATRIX; PROTEIN-22; POLYMERASE-CHAIN-REACTION; CARE PROTEOMIC ASSAY; BTA TRAK; ASSAY; UROTHELIAL CARCINOMA; VOIDED-URINE; GENE-EXPRESSION; FOLLOW-UP; Medicine, Research & Experimental

    Abstract

    Bladder cancer is one of the most prevalent cancers worldwide. Early detection of bladder tumors is critical for improved patient outcomes. The standard method for detection and surveillance of bladder tumors is cystoscopy with urinary cytology. Limitations of cystoscopy and urinary cytology have brought to light the need for more robust diagnostic assays. Ideally, such assays would be applicable to noninvasively obtained, voided urine, and be designed not only for diagnosis, but also for monitoring disease recurrence and response to therapy. Consequently, the development of a noninvasive urine-based assay would be of tremendous benefit to both patients and healthcare systems. This article reports some of the more prominent urine-based biomarkers reported in the literature. In addition, some new technologies that have been used to identify novel urinary biomarkers are highlighted.

    Journal Title

    Biomarkers in Medicine

    Volume

    7

    Issue/Number

    5

    Publication Date

    1-1-2013

    Document Type

    Review

    Language

    English

    First Page

    779

    Last Page

    790

    WOS Identifier

    WOS:000324474800018

    ISSN

    1752-0363

    Share

    COinS